PHOENIX, May 26, 2015 /PRNewswire/ -- Ashion Advanced Individual Medicine (AIM), a full-service provider of premier personalized medicine services focused on delivering advanced medical solutions and treatment options for healthcare providers and the patients they serve, today announced its launch into the precision medicine space.
For hospitals, clinics and other healthcare providers, AIM will provide access to advanced genomic testing that will enable their physicians to use the billions of bits of information derived from the human genome to discover difficult-to-diagnose illnesses, and utilize the molecular-based information to develop new treatment recommendations for patients with serious illnesses, especially cancer.
For hospitals, universities and other medical institutions, AIM will provide a means to leverage the potential of the human genome and the diagnostic tools necessary to capitalize on that potential, assisting with the discovery of new patient treatment options, clinical research and medical advances, while developing targeted therapies that may not have been considered previously for individual patients.
Through the introduction of its Personalized Medicine Centers, AIM will also provide institutions with guidance on everything from education, training, data management software and clinical research opportunities, to assistance with marketing, branding and reimbursement.
"We want to harness the power of the human genome to provide patients with the promise inherent in our name: Advanced Individual Medicine," said Edgar Staren, M.D., Ph.D., MBA, President of AIM, himself a cancer survivor.
"To achieve our aims, we will empower institutions with access to the latest in genetic technology, providing a means to analyze the symptoms of patients more precisely, provide genetically-based diagnoses, and help direct the highest quality of care to achieve enhanced quality of life and extended survival."
Dr. Staren practiced as a surgical oncologist in Chicago while earning a Ph.D. in immunology and microbiology and moving into the field of clinical research as well. He subsequently earned an MBA to hone his business management skills.
At 46, while serving as medical director of the Medical College of Ohio Cancer Institute, Dr. Staren was diagnosed with an aggressive sarcoma in his leg. That experience provided him with a heightened empathy for the needs of cancer patients, and helped spur his drive to vastly improve the care they receive.
In order to facilitate adoption of new treatment strategies, AIM provides physician, clinician, administration and patient education resources, and is also prepared to assist institutions with on-demand access to clinical research nurse managers, tumor boards and panels of expert physicians.
"There is a higher form of medicine now available to equip medical institutions with the means to access the very latest in genetic technology and thereby improve the lives of their patients," Dr. Staren said.
About Advanced Individual MedicineAdvanced Individual Medicine (AIM), an Ashion Company is a subsidiary of Ashion PMed Management LLC. AIM's vision is to be recognized as the global leader in the delivery of personalized medicine solutions. AIM's mission is to provide premier personalized medicine solutions for healthcare providers by continuously advancing the knowledge and services to the patients they serve. AIM develops and manages comprehensive Personalized Medicine Centers (PMC's) with partner regional healthcare systems. More information is available at www.AshionAIM.com.
Press Contact:Melissa Ray, MBA, BSEVice President, AdministrationAshion Advanced Individual Medicine, [email protected] www.AshionAIM.com
Advertisement
For hospitals, clinics and other healthcare providers, AIM will provide access to advanced genomic testing that will enable their physicians to use the billions of bits of information derived from the human genome to discover difficult-to-diagnose illnesses, and utilize the molecular-based information to develop new treatment recommendations for patients with serious illnesses, especially cancer.
Advertisement
For hospitals, universities and other medical institutions, AIM will provide a means to leverage the potential of the human genome and the diagnostic tools necessary to capitalize on that potential, assisting with the discovery of new patient treatment options, clinical research and medical advances, while developing targeted therapies that may not have been considered previously for individual patients.
Through the introduction of its Personalized Medicine Centers, AIM will also provide institutions with guidance on everything from education, training, data management software and clinical research opportunities, to assistance with marketing, branding and reimbursement.
"We want to harness the power of the human genome to provide patients with the promise inherent in our name: Advanced Individual Medicine," said Edgar Staren, M.D., Ph.D., MBA, President of AIM, himself a cancer survivor.
"To achieve our aims, we will empower institutions with access to the latest in genetic technology, providing a means to analyze the symptoms of patients more precisely, provide genetically-based diagnoses, and help direct the highest quality of care to achieve enhanced quality of life and extended survival."
Dr. Staren practiced as a surgical oncologist in Chicago while earning a Ph.D. in immunology and microbiology and moving into the field of clinical research as well. He subsequently earned an MBA to hone his business management skills.
At 46, while serving as medical director of the Medical College of Ohio Cancer Institute, Dr. Staren was diagnosed with an aggressive sarcoma in his leg. That experience provided him with a heightened empathy for the needs of cancer patients, and helped spur his drive to vastly improve the care they receive.
In order to facilitate adoption of new treatment strategies, AIM provides physician, clinician, administration and patient education resources, and is also prepared to assist institutions with on-demand access to clinical research nurse managers, tumor boards and panels of expert physicians.
"There is a higher form of medicine now available to equip medical institutions with the means to access the very latest in genetic technology and thereby improve the lives of their patients," Dr. Staren said.
About Advanced Individual MedicineAdvanced Individual Medicine (AIM), an Ashion Company is a subsidiary of Ashion PMed Management LLC. AIM's vision is to be recognized as the global leader in the delivery of personalized medicine solutions. AIM's mission is to provide premier personalized medicine solutions for healthcare providers by continuously advancing the knowledge and services to the patients they serve. AIM develops and manages comprehensive Personalized Medicine Centers (PMC's) with partner regional healthcare systems. More information is available at www.AshionAIM.com.
Press Contact:Melissa Ray, MBA, BSEVice President, AdministrationAshion Advanced Individual Medicine, [email protected] www.AshionAIM.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ashion-advanced-individual-medicine-launches-premier-personalized-medicine-services-to-leverage-the-power-of-the-human-genome-300088376.html
SOURCE Ashion Advanced Individual Medicine
